“Magnus has over the past decade played an instrumental role in building a global leading Specialty Pharma platform in animal health with a strong financial track record, combining M&A driven and organic growth”, says Alireza Tajbakhsh, CEO of Vimian, and continues:

“I would like to sincerely thank Magnus for his achievements and wish him best of luck for the future. We will start the recruitment of a new Head of Specialty Pharma with immediate effect and in the meantime, I am pleased that Carl-Johan Zetterberg Boudrie, in addition to his role as CFO, has accepted the position as interim Head of Specialty Pharma working in parallel with Magnus Kjellberg during spring.”

Commenting on his departure, Magnus Kjellberg says:

“I am proud of what the Specialty Pharma team, and Vimian as a whole, have achieved during my tenure with the company. Having worked with Ali as a colleague over the last four years, I am confident that he is the right CEO to lead Vimian, and as the Specialty Pharma segment now stands strong and is well-positioned for continued success, I found the timing right for me to pursue new opportunities. I look forward to working closely with Carl-Johan and the management team to ensure a smooth transition during spring.”